New Zealand adds Covaxin and Covishield in recognised COVID-19 vaccine

Thursday, November 18, 2021

New Zealand has recognied Covaxin and Covishield, the two most widely-used vaccines in India’s vaccination drive against the coronavirus disease (Covid-19).

The announcement in this regard was made by Muktesh Pardeshi, India’s high commissioner to the island nation, who described it as a ‘positive’ decision by the New Zealand government.

The New Zealand government’s decision, meanwhile, comes at a time when India has, for the first time since March last year, opened its borders for fully vaccinated foreign travellers.

Under the rule, which came into effect from November 15, passengers from countries with which India has mutual vaccination certificates will not have to undergo a post-arrival Covid-19 test, which is, however, mandatory for people coming from the other nations.

Covaxin and Covishield were the first two jabs to receive emergency use authorisation (EUA) from the Drugs Controller General of India (DCGI) for the nationwide inoculation drive, which commenced on January 16. The former has been developed by the Hyderabad-based Bharat Biotech International Limited, and is the first made-in-India anti-Covid shot. The latter is the Indian variant of Britain’s Astrazeneca vaccine, and manufactured locally by the Pune-based Serum Institute of India (SII).

« Back to Page

• International Passenger Numbers in Perth Airport Have Rebounded to Pre-Covid Levels

• Explore the enchantment of our sugar bush: A journey into maple syrup magic

• Siargao’s tourist arrivals surge, marks stellar growth in Philippines

• Interview with Ahmad Al-Hmoud of the Jordan Tourism Board at FITUR

• AIME 2024 marks 63 per cent increase in exhibitors from previous year